May 05, 2020
Journal of Neuroinflammation Article Shows ZyVersa's Inflammasome Inhibitor, IC 100, Improves Functional Outcomes in an Animal Model of Multiple Sclerosis
Aug 01, 2019
Rewind Therapeutics Awarded EUR2.9 Million VLAIO Grant to Discover and Develop Novel Drug Candidates for Myelin-related Neurological Diseases
Jul 09, 2019
Publication Confirms AxoSim's Nerve-on-a-Chip® Technology Embodies Key Nervous System Functions Needed to Speed New Drug R&D
Feb 06, 2019
Rewind Therapeutics Expands Scientific Advisory Board with Addition of Professors Robin Franklin and Catherine Lubetzki, Bringing Further Expertise in Myelin and Multiple Sclerosis Research
Oct 10, 2018
Rewind Therapeutics Builds Scientific Advisory Board to Accelerate Its Development of New Therapies for Myelin-Related Diseases
Oct 03, 2018
Rewind Therapeutics Appoints Leading Neuroscience Drug Developer Ian J. Reynolds as Chief Executive Officer
Apr 17, 2018
National MS Society Commits $14.2 Million to New Research to Stop Multiple Sclerosis, Restore Function and End MS Forever
Feb 12, 2018
Experimental Therapy Restores Nerve Insulation Damaged by Disease
Feb 02, 2018
Clene Nanomedicine Announces Preclinical Results of A Novel Gold Nanocrystal Remyelinating Treatment for Multiple Sclerosis at ACTRIMS Forum Annual Meeting
Dec 13, 2017
Cambridge University Scientist Wins Innovation Prize for Multiple Sclerosis Research
Oct 10, 2017
National MS Society Commits Nearly $14 Million to New Research to Stop Multiple Sclerosis, Restore Function and End MS Forever